Faessel, H M <br/><br/>
Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin -6-yl)-(S)-ethyl]-2,5-thienoylamino-L-glutamic acid (AG2034): comparison across sensitive and resistant human tumor cell lines.  [electronic resource] 

 -  Biochemical pharmacology  Mar 1999 
 - 567-77 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0006-2952 
<br/><br/><label>Standard No.: </label>10.1016/s0006-2952(98)00315-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma<br/>Antineoplastic Agents--toxicity<br/>Carcinoma, Squamous Cell<br/>Cell Division--drug effects<br/>Colonic Neoplasms<br/>Drug Resistance, Multiple<br/>Drug Synergism<br/>Folic Acid--pharmacology<br/>Folic Acid Antagonists--toxicity<br/>Glutamates--toxicity<br/>Head and Neck Neoplasms<br/>Humans<br/>Hydroxymethyl and Formyl Transferases--antagonists & inhibitors<br/>Kinetics<br/>Lung Neoplasms<br/>Phosphoribosylglycinamide Formyltransferase<br/>Pyrimidines--toxicity<br/>Trimetrexate--toxicity<br/>Tumor Cells, Cultured